Salesforce.com to B...
Health Care: Drugs
Achillion Pharmaceuticals Inc. (ACHN: NASDAQ)
$6.95 0.06 | 0.87%
06/04/12 - 02:38 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 0.71 | 0.58 | 0.98 |
| Price to Sales (TTM) | 182.24 | 4.62 | 1.42 |
| Price to Book (MRQ) | 7.61 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 7.61 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -11.50 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -12.30 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 3,729.00 | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -89.90 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | n.a. | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -10.79 | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 6.90 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 7.10 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.01 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 0.01 | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 83.50 | 47.70 |
| EBITD Margin (TTM) | n.a. | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -1,074.93 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -16.18 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -58.40 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -67.00 | 2.20 | 2.50 |
| Return on Investment (TTM) | -66.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -89.50 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 55,646.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -900,292.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | 48.60 | 5.80 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.00 | 0.40 | 0.40 |
Portfolios with ACHN
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- UserThe cash burners
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Hep C Stocks on Wall Str...
- Contributor10 Health-Care Stocks Outpe...
- ContributorHep C Drug Stocks in the Sp...
- UserStocks Under $5
- UserLegal Tender II
- UserTop Picks Under $5 for 2011...
- ContributorTop Stock Picks Under $5 fo...
Latest ACHN Headlines from TheStreet
- Grading Hep C Stocks Exiting EASL Confab 04.23.12 | 09:04 am
- Achillion Stock Gaps Down On Today's Open (ACHN) 04.19.12 | 08:04 am
- For Biotech, 'Fail' is Making a Big Comeback 03.12.12 | 08:03 am
- 8 Stocks Rising on Monster Volume 02.17.12 | 02:02 pm
- Hedge Funds Catch Hep C Fever 02.15.12 | 10:02 am
- Biotech Stock Mailbag: Vical, Hep C Drugs 01.27.12 | 07:01 am
- BioLineRx: Tuesday's Hot Hep C Drug Stock 01.24.12 | 11:01 am
- Idenix Pharma Buyout Likely: Survey 01.20.12 | 03:01 pm
- Biotech Stock Mailbag: Celldex, Hep C Bubble, Al Mann Anger 01.20.12 | 05:01 am
- 4 Companies That Are Bleeding Cash 01.13.12 | 07:01 am
Press Releases for ACHN
- Emerald Holds Annual Groundhog Day Investment Forum - Business Wire 02.06.12 | 08:02 am
Partner Headlines for ACHN
- Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C - Benzinga 04.21.12 | 04:04 pm
- UPDATE: Bank of America Raises Actuant's PT - Benzinga 03.08.12 | 01:03 pm
- Gilead's Electron Data Brings Some Reality Back To The Hep C Market - Seeking Alpha 02.17.12 | 09:02 am
- 10 Biotech Stocks With 100% Upside In 2012: Part One - Seeking Alpha 02.09.12 | 10:02 am
- Company News for January 25, 2012 - Corporate Summary - Zacks 01.25.12 | 10:01 am
- Afternoon Movers; Negative Euro News - Benzinga 01.24.12 | 04:01 pm
- Benzinga's M&A Chatter for Friday January 20, 2012 - Benzinga 01.20.12 | 06:01 pm
- End-of-Day Market Summary for January 20, 2012 - Benzinga 01.20.12 | 04:01 pm
- Afternoon Movers; Markets Moved Sideways - Benzinga 01.20.12 | 04:01 pm
- 10 Biotech Stocks With Strong Corporate Governance - Seeking Alpha 01.18.12 | 09:01 am
